Shares of Customers Bancorp (CUBI) have gained 1.6% over the past four weeks to close the last trading session at $65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $84.75 indicates a potential upside of 30.4%.The average comprises eight short-term price targets ranging from a low of $68.00 to a high of $95.00, with a standard deviation of $9.5. While the lowest estimate indic ...

Masimo (MASI) closed the last trading session at $147.03, gaining 0% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $186.14 indicates a 26.6% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $14.16. While the lowest estimate of $168.00 indicates a 14.3% increase from the current price level, the most optimistic analyst expect ...

Core Viewpoint - Nektar Therapeutics (NKTR) shares have shown a 1.4% increase over the past month, closing at $57.67, with analysts suggesting a potential upside of 62.8% based on a mean price target of $93.86 [1][11]. Price Targets and Analyst Consensus - The average price target for NKTR is derived from seven short-term estimates, ranging from a low of $30.00 to a high of $120.00, with a standard deviation of $29.13, indicating variability in analyst predictions [2]. - The lowest estimate suggests a potential decline of 48%, while the highest indicates an upside of 108.1% [2]. - A smaller standard deviation reflects greater agreement among analysts regarding price movement, which can be a useful starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about NKTR's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.7%, with two estimates moving higher and no negative revisions [12]. - NKTR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][7]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8][10].

Core Viewpoint - Ambac Financial Group (AMBC) shares have increased by 19.4% in the past four weeks, closing at $9.91, with a mean price target of $14.67 indicating a potential upside of 48% [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.51, where the lowest estimate is $10.00 (0.9% increase) and the highest is $19.00 (91.7% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, one estimate has increased, leading to a 3.7% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - AMBC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target may not be a reliable indicator of potential gains, but the implied direction of price movement is a useful guide [14]

Core Viewpoint - Veritone, Inc. (VERI) has seen a 21.7% increase in share price over the past four weeks, closing at $6.39, with analysts suggesting a potential upside of 65.9% based on a mean price target of $10.6 [1][11]. Price Targets - The average price target for VERI ranges from a low of $3.00 to a high of $25.00, with a standard deviation of $8.5, indicating significant variability among analyst estimates [2]. - The lowest estimate suggests a decline of 53.1% from the current price, while the highest estimate indicates a potential upside of 291.2% [2]. Analyst Consensus - There is strong agreement among analysts regarding VERI's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 1.4% over the past month, with no negative revisions, indicating positive sentiment [12]. Zacks Rank - VERI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as analysts may set overly optimistic targets due to business incentives [3][8][10].

Core Viewpoint - Liquidia Corporation (LQDA) has seen a 9.7% increase in share price over the past four weeks, closing at $26.42, with a potential upside of 62.3% based on Wall Street analysts' mean price target of $42.89 [1] Price Targets - The average price target consists of nine estimates ranging from a low of $6.00 to a high of $67.00, with a standard deviation of $16.92, indicating variability among analysts [2] - The lowest estimate suggests a decline of 77.3%, while the highest indicates a potential upside of 153.6% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][9] Analyst Sentiment - Analysts have shown increasing optimism about LQDA's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, four earnings estimates have been revised upward, leading to a 45.4% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - LQDA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a useful indication of the expected direction of price movement [14]

Core Viewpoint - Transcat, Inc. (TRNS) shares have increased by 7.6% recently, with analysts suggesting a potential upside of 34.6% based on a mean price target of $106.75 [1] Price Targets - The average price target for TRNS ranges from a low of $95.00 to a high of $116.00, with a standard deviation of $9.03, indicating a relatively high agreement among analysts [2] - The lowest estimate suggests a 19.8% increase, while the highest points to a 46.3% upside [2] Analyst Sentiment - Analysts are optimistic about TRNS's earnings prospects, as indicated by upward revisions in earnings estimates, which historically correlate with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has risen by 4.1% over the past month, with no negative revisions [12] Zacks Rank - TRNS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Mobileye Global (MBLY) shares have increased by 10.2% in the last four weeks, closing at $15.2, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $19.13, representing a 25.9% upside [1] Price Targets and Analyst Consensus - The average of 23 short-term price targets ranges from a low of $12.00 to a high of $30.00, with a standard deviation of $4.35, indicating variability in estimates; the lowest estimate suggests a decline of 21.1%, while the highest points to a 97.4% upside [2] - Analysts' price targets can mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Potential Upside - Analysts have shown increasing optimism about MBLY's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 4.4% over the past month, with one estimate increasing and no negative revisions [12] - MBLY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] Conclusion on Price Movement - While consensus price targets may not reliably indicate the extent of MBLY's potential gains, they do provide a useful guide for the direction of price movement [14]

Group 1 - XOMA Royalty's shares have increased by 22.2% over the past four weeks, closing at $31.37, with a mean price target of $64.67 indicating a potential upside of 106.2% [1] - The average price targets range from a low of $35.00 to a high of $104.00, with a standard deviation of $35.5, suggesting variability in analysts' estimates [2] - Analysts show strong agreement on XOMA's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - The Zacks Consensus Estimate for XOMA's current year has increased by 1885.7%, with two estimates moving higher and no negative revisions [12] - XOMA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Syndax Pharmaceuticals (SNDX) has shown a significant price increase of 45.4% over the past four weeks, with a mean price target of $34.75 indicating a potential upside of 158.4% from the current price of $13.45 [1] Price Targets and Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $12.74, where the lowest estimate is $17.00 (26.4% increase) and the highest is $56.00 (316.4% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about SNDX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 11.9% over the past month, with five estimates revised upward and no negative revisions [12] - SNDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]